MSK Report News

Thursday, February 25, 2010 Arthritis: Physical Inactivity and Obesity Raises Arthritis Risk, Especially in Women
Arthritis rates are higher in the US than in Canada, according to a new study...

Wednesday, February 17, 2010 BioPharm Business News and Perspectives: AstraZeneca to Enter the RA Market
AstraZeneca is entering the rheumatoid arthritis (RA) market by gaining rights to Rigel’s RA drug...

Thursday, February 11, 2010 BioPharm Business News and Perspectives: Merck Settles Vioxx Lawsuits
Merck & Co. has agreed to settle lawsuits over their withdrawn painkiller Vioxx with a strengthening of safety procedures, change of leadership, and payment of legal fees...

Wednesday, February 10, 2010 Imaging: FDA Wants to Reduce Radiation Exposure from Medical Scans
Widespread use of CT scans and fluoroscopy is exposing some patients to unnecessary amounts of radiation, and raising their risk of cancer...

Tuesday, February 09, 2010 Procedures: Minimally Invasive Hip Replacements Growing in Popularity
Orthopedic surgeons have developed techniques to make hip replacement operations less invasive, cutting down the length of time patients spend in the hospital and speeding up total recovery time...

Tuesday, February 02, 2010 BioPharm Business News and Perspectives: UCB to Exit the Primary Care Market in the US
Instead, the company plans to focus on becoming a patient-centric global biopharmaceutical leader...

Monday, February 01, 2010 BioPharm Business News and Perspectives: CP-690,550, Pfizer's Oral JAK Inhibitor, Demonstrates Response in Patients with Active Rheumatoid Arthritis
Pfizer’s oral JAK Inhibitor CP-690,550 shows efficacy at improving the pain, function, and health status of RA patients...

Thursday, January 28, 2010 Pain: Pain Pumps May Lead to Development of Chondrolysis
Hundreds of patients have developed the relatively rare ailment after the use of postsurgical pain pumps...

Wednesday, January 27, 2010 Arthritis: RA Development Can Be Predicted by Inflammatory Cytokines
Increased concentrations of proinflammatory cytokines can predict onset of RA before symptoms develop...

Tuesday, January 26, 2010 BioPharm Business News and Perspectives: FDA Approves Tocilizumab for Refractory RA
Tocilizumab (Actemra) has been approved for adults with moderate-to-severe RA who have not achieved adequate response with other TNF therapies...